Company Announcements - 2018
-
PeriCoach Production Update18 December 2018
Analytica has re-opened sales in the US and its territories after resuming production with a new Contract Manufacturer, re-registering its establishments with the USFDA, and clearing the first shipment through US customs.
-
Results of Annual General Meeting22 November 2018
Analytica presents the proxy votes for resolutions at the Annual General Meeting. The company also presents the Chairman's address to shareholders and slides from the CEO presentation.
-
Appendix 4C31 October 2018
Analytica presents its quarterly cash flow report to 30 September 2018.
-
Notice of Option Expiry30 October 2018
Analytica gives notice of unlisted options expiring 29 October 2018.
-
Notice of Annual General Meeting and Proxy Form19 October 2018
Analytica advises that the 2018 Annual General Meeting will be held in Room E, Level 1, Christie Conference Centre, 320 Adelaide St Brisbane at 10:00am Thursday 22nd November 2018. Also included with this notice is a sample voting proxy form with instructions.
-
PeriCoach Manufacturing Update8 October 2018
Analytica has recently signed a manufacturing services agreement with an Australian-based contract manufacturer.
-
Change in Registered Office3 September 2018
-
Appendix 4G and Corporate Government Statement30 August 2018
Analytica presents its Appendix 4G and Corporate Governance Statements at 29 Aug 2018.
-
Appendix 4E - Preliminary Final Report30 August 2018
Analytica presents its Appendix 4E and Financial Statements for the year ended 30 June 2018.
-
PeriCoach® Real-World Data Analysis Reveals Statistically Significant Reduction in Incontinence Symptoms Within 3 Weeks21 August 2018
Analysis of PeriCoach v3 real-world data conducted by an independent biostatistician reveals significant improvements in pelvic floor strength in five weeks, and reduction in urine volume and leakage episodes in only three weeks
-
USFDA Issues Warning Letters to Vaginal Rejuvenation Laser Manufacturers for Deceptive Treatment Claims1 August 2018
Analytica would like to direct shareholders to a recent USFDA announcement regarding vaginal rejuvenations.
-
Appendix 3Y31 August 2018
.
-
Appendix 4C31 July 2018
Analytica presents its quarterly cash flow report to 30 June 2018.
-
Appendices 3Y and Forms 604 from May Options and Placements15 June 2018
-
Analytica raises $1,532m from Options and Placements12 June 2018
-
PeriCoach Expands Clinical Indication to Include Pelvic Organ Prolapse2 May 2018
Analytica is pleased to announce that it has received Australian TGA clearance for the expanded clinical indication for the PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse.
-
Appendix 4C30 April 2018
Analytica presents its quarterly cash flow report to 31 March 2018.
-
Change in PeriCoach Manufacturer for US Market. Reduction in Cost of Goods.23 March 2018
Analytica is selecting a new manufacturer for its PeriCoach product in the US market following the decision by the product’s previous manufacturer of record to withdraw USFDA registration.
-
Appendix 4D28 February 2018
Analytica presents its Appendix 4D - Half year results to 31 December 2017.
-
Appendix 3Y (x3) and Form 6049 February 2018
Change of Director's Interest Notice for Dr Michael Monsour, Dr Peter Corr, and Mr Ross Mangelsdorf, and Form 604 for Dr Michael Monsour.
-
Analytica Raises $1.039M7 February 2018
Analytica has raised $1.039M of capital from shareholders exercising their options and from private placements.
-
Senate Inquiry Submission30 January 2018
Analytica presents the Company’s submission to the Australian Senate Committee “Inquiry into the number of women in Australia who have had transvaginal mesh implants and related matters”.
-
Appendix 4C29 January 2018
Analytica presents its quarterly cash flow report for the period ending 31 Dec 2017.